Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 1-4

  Ozsan, Guner Hayri ^a   Micallef, Ivana N ^b   Dispenzieri, Angela ^b   Kumar, Shaji ^b   Lacy, Martha Q ^b   Dingli, David ^b   Hayman, Suzanne R ^b   Buadi, Francis K ^b   Wolf, Robert C ^b   Gastineau, Dennis A ^b   Hogan, William J ^b   Gertz, Morie A ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GROWTH FACTOR; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD; CANCER CHEMOTHERAPY; CD34 SELECTION; CELL COUNT; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THROMBOCYTE COUNT;

AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC TESTS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; KINETICS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS;

EID: 84055212507     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22179     Document Type: Article

References (37)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
3. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-3759.
4. Mehta J, Singhal S. Current status of autologous hematopoietic stem cell transplantation in myeloma. Bone Marrow Transplant 2008; 42( Suppl 1): S28-S34.
5. Jansen J, Hanks S, Thompson JM, et al. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005; 9: 37-50.
6. Gidron A, Singh V, Egan K, Mehta J. Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: What should the threshold required for apheresis be? Bone Marrow Transplant 2008; 42: 439-442.
7. Bolwell BJ, Pohlman B, Rybicki L, et al. Patients mobilizing large numbers of CD34+ cells ("super mobilizers") have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007; 40: 437-441.
8. Jillella AP, Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev 2004; 13: 598-606.
9. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
10. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
11. Stiff PJ, Micallef I, Nademanee AP, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011; 17: 1146-1153.
12. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
13. Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003; 31: 319-329.
14. Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44: 777-784.
15. Mendrone AJr, Arrais CA, Saboya R, et al. Factors affecting hematopoietic progenitor cell mobilization: An analysis of 307 patients. Transfus Apher Sci 2008; 39: 187-192.
16. Pastore D, Specchia G, Mestice A, et al. Good and poor CD34+ cells mobilization in acute leukemia: Analysis of factors affecting the yield of progenitor cells. Bone Marrow Transplant 2004; 33: 1083-1087.
17. Perseghin P, Terruzzi E, Dassi M, et al. Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009; 41: 33-37.
18. Akhtar S, Weshi AE, Rahal M, et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769-778.
19. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
20. Gandhi MK, Jestice K, Scott MA, et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9-13.
21. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
22. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
23. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042.
24. Lefrere F, Zohar S, Ghez D, et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: Results from a monocentric study of 82 patients. Bone Marrow Transplant 2006; 37: 725-729.
25. Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547-1553.
26. Perea G, Sureda A, Martino R, et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001; 80: 592-597.
27. Gertz MA, Wolf RC, Micallef IN, Gastineau DA. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45: 1396-1403.
28. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
29. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
30. Micallef IN, Ho AD, Klein LM, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2010; 46: 350-355.
31. Micallef IN, Stiff PJ, DiPersio JF, et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: Results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-1586.
32. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
33. Nimmagadda S, Sweiss K, Mahmud N, et al. Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF. Bone Marrow Transplant 2010; 45: 1121-1122.
34. Passos-Coelho JL, Braine HG, Davis JM, et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 1995; 13: 705-714.
35. Duong HK, Bolwell BJ, Rybicki L, et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: A simple method using day 1 CD34+ cell yield. J Clin Apher.
36. Sinha S, Gastineau D, Micallef I, et al. Predicting PBSC harvest failure using circulating CD34 levels: Developing target-based cutoff points for early intervention. Bone Marrow Transplant.
37. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150: 647-662.